GlassScriptPhysician profile
Vinay Sikand
NPI 1568499374
$96,226.17
in general payments reported to CMS, 2019-2025
48 companies · $2,878 in 2025
The $2,878 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $10K · 2021: $14K · 2022: $10K · 2023: $35K · 2024: $3,204 · 2025: $2,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $11K · Travel and Lodging: $5,264 · Education: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,375.00 |
| Food and Beverage | $10,701.09 |
| Travel and Lodging | $5,263.53 |
| Education | $431.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $72,743.98 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $8,632.31 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Chiesi USA, INC. | $1,811.89 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,495.93 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Philips North America LLC | $1,389.43 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Actelion Pharmaceuticals US, INC. | $1,287.25 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Uk Limited | $1,032.67 | 2022 | |
| Genzyme Corporation | $996.10 | 2019-2025 | |
| Mylan Specialty L.P. | $869.35 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $851.78 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $477.14 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $463.89 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Inspire Medical Systems, INC. | $456.47 | 2023-2025 | Inspire |
| Insmed, INC. | $390.96 | 2019-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $337.65 | 2019-2024 | Xolair |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $320.83 | 2022-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $306.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $281.63 | 2019-2025 | |
| Amgen INC. | $278.75 | 2022-2025 | Tezspire |
| Baxter Healthcare | $223.91 | 2022-2025 | Hillrom - Life 2000 Ventilation System |
| Viatris Specialty LLC | $181.31 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $171.27 | 2021-2025 | Aralast |
| Teva Pharmaceuticals USA, INC. | $170.15 | 2019-2023 | Airduo Digihaler |
| Electromed, INC. | $148.03 | 2019-2024 | Smartvest |
| Silk Road Medical, INC. | $122.03 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Novartis Pharmaceuticals Corporation | $105.61 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $99.91 | 2023-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $92.99 | 2025 | |
| Mallinckrodt Hospital Products INC. | $53.07 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $51.92 | 2023-2024 | Lumryz |
| Axsome Therapeutics, INC. | $51.55 | 2025 | Sunosi |
| Janssen Pharmaceuticals, INC | $39.51 | 2022-2023 | Xarelto |
| Verona Pharma, INC. | $35.80 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $30.79 | 2024-2025 | Veltassa, Zemaira |
| Resmed Corp | $29.31 | 2020 | |
| Circassia INC. | $27.82 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $27.15 | 2020-2021 | |
| Breathe Technologies, INC. | $24.11 | 2019 | |
| Inogen, INC. | $22.49 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Azurity Pharmaceuticals, INC. | $17.56 | 2025 | Alvesco |
| Pfizer INC. | $16.63 | 2023 | |
| Merck Sharp & Dohme LLC | $15.52 | 2023 | |
| Lilly USA, LLC | $15.24 | 2025 | Zepbound |
| Nabriva Therapeutics, Plc | $14.30 | 2022 | |
| Itamar Medical INC | $13.30 | 2025 | Watchpatone |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,435.11 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Sikand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.